Exploitation of recombinant DNA and sequencing technologies has led to a new concept in
vaccination in which isolated epitopes, capable of stimulating a specific immune response …

The timelines for developing vaccines against infectious diseases are lengthy, and often
vaccines that reach the stage of large phase 3 field trials fail to provide the desired level of …

In vivo protection by antimicrobial neutralizing Abs can require the contribution of effector
functions mediated by Fc-Fcγ receptor (Fc-FcγR) interactions for optimal efficacy. In …

Systems approaches have been used to describe molecular signatures driving immunity to
influenza vaccination in humans. Whether such signatures are similar across multiple …

The usefulness of live attenuated virus vaccines has been limited by suboptimal
immunogenicity, safety concerns or cumbersome manufacturing processes and techniques …

Current influenza vaccines provide limited protection against circulating influenza A viruses.
A universal influenza vaccine will eliminate the intrinsic limitations of the seasonal flu …

Antibodies are widely considered to be a frequent primary and often mechanistic correlate of
protection of approved vaccines; thus evaluating the antibody response is of critical …

Influenza viruses infect approximately 20% of the global population annually, resulting in
hundreds of thousands of deaths. While there are Food and Drug Administration (FDA) …

Background In children, necrotizing pneumonia (NP) is an uncommon, severe complication
of pneumonia. It is characterized by destruction of the underlying lung parenchyma resulting …

Influenza hemagglutinin (HA) is the primary target of the humoral response during
infection/vaccination. Current influenza vaccines typically fail to elicit/boost broadly …